← All trials
NCT02283203
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2015
- Primary completion
- Mar 1, 2016
- Completion date
- Mar 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Unipharm, Inc.Lead sponsor
- University of PatrasOverall official - principal investigator
- University of AthensOverall official - principal investigator
- General Hospital of ChalkidaOverall official - principal investigator
- Thriasion Elefsis General HospitalOverall official - principal investigator
- Aristotle University of ThessalonikiOverall official - principal investigator
- General Hospital of ChalkidaCollaborator
- University of CreteCollaborator
- University of PatrasCollaborator
- University of AthensCollaborator
- Thriasion Elefsis General HospitalCollaborator
- University of CreteOverall official - principal investigator
- Aristotle University of ThessalonikiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.